Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer

Oncologist

Volumn 11, Issue 10, 2006, Pages 1081-1088

  Macaskill, E Jane ^a   Renshaw, Lorna ^a   Dixon, J Michael ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Anastrozole; Aromatase inhibitors; Breast cancer; Elderly; Exemestane; Letrozole; Neoadjuvant; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; DOXORUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; PACLITAXEL; TAMOXIFEN;

ALOPECIA; ARTHRALGIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COMORBIDITY; ELDERLY CARE; FATIGUE; HEADACHE; HEART FAILURE; HORMONAL THERAPY; HOT FLUSH; HUMAN; INTERMETHOD COMPARISON; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SURGICAL MORTALITY; THROMBOEMBOLISM; TREATMENT RESPONSE; VAGINA BLEEDING;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; RECEPTORS, ESTROGEN; RISK FACTORS; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES;

EID: 33751211861     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-10-1081     Document Type: Review

References (28)

1. Yancik R, Wesley MN, Ries LAG et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001;285:885-892.
2. Pierga JY, Girre V, Laurence V et al. Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age. Breast 2004;13:369-375.
3. Semiglazov VF, Semiglazov V, Ivanov V et al. The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER positive breast cancer. Proc Am Soc Clin Oncol 2004;22:519.
4. Guarneri V, Broglio K, Kau SW et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006;24:1037-1044.
5. Gazet JC, Ford HT, Coombes RC et al. Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur J Surg Oncol 1994;20:207-214.
6. Kenny FS, Robertson JF, Ellis IO et al. Long-term follow-up of elderly patients randomised to primary tamoxifen or wedge mastectomy as initial therapy for operable breast cancer. Breast 1998;7:335-339.
7. Fentiman IS, Christiaens MR, Paridaens R et al. Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy. Eur J Cancer 2003;39:309-316.
8. Mustacchi G, Ceccherini R, Milani S et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol 2003;14:414-420.
9. Fennessy M, Bates T, MacRae K et al. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br J Surg 2004;91:699-704.
10. Bates T, Fennessy M, Riley DL et al. Breast cancer in the elderly: surgery improves survival. The results of a Cancer Research Campaign trial. Eur J Cancer 2001;37(suppl 5):7.
11. Horobin JM, Preece PE, Dewar JA et al. Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br J Surg 1991;78:213-217.
12. Dixon JM. Neoadjuvant therapy: surgical perspectives. In: Miller WR, Ingle JN, eds. Endocrine Therapy in Breast Cancer. New York: Marcel Dekker, 2002:197-212.
13. Eiermann W, Paepke S, Appfelstaedt J et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001;12:1527-1532.
14. Ellis MJ, Coop A, Singh B et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 2003;63:6253-6231.
15. Renshaw L, Murray J, Young O et al. Is there an optimal duration of neoadjuvant letrozole therapy? Breast Cancer Res Treat 2004;88(suppl 1):S36.
16. Dixon JM, Renshaw L, Bellamy C et al. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res 2000;6:2229-2235.
17. Smith I, Dowsett M, on behalf of IMPACT Trialists. Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. Breast Cancer Res Treat 2003;82(suppl 1):S6.
18. Dowsett M, A'Hern R, Smith I et al. Ki67 after 2 weeks' endocrine treatment predicts relapse-free survival (RFS) in the IMPACT trial. Breast Cancer Res Treat 2005;94(suppl 1):Abstract.
19. Cataliotti L, Buzdar A, Noguchi S et al. Efficacy of preoperative anastrozole compared with tamoxifen in postmenopausal women with hormone receptor positive breast cancer. Presented at the 4th European Breast Cancer Conference, Hamburg, Germany, March 17, 2004.
20. Miller WR, Dixon JM. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control 2002;9(suppl 2):9-15.
21. Krainick U, Astner A, Jonat W et al. Phase II study to define safety and efficacy of exemestane as preoperative therapy for postmenopausal patients with primary breast cancer - final results of the German Neoadjuvant Aromasin Initiative (GENARI). Breast Cancer Res Treat 2003;82(suppl 1):S55.
22. Tubiana-Hulin M, Spyratos F, Becette V et al. Phase II study of neo-adjuvant exemestane in postmenopausal patients with operable breast cancer. Breast Cancer Res Treat 2003;82(suppl 1):S106.
23. Semiglazov VF, Semiglazov VV, Ivanov VG et al. Neoadjuvant endocrine therapy: exemestane vs tamoxifen in postmenopausal ER+ breast cancer patients (T1-4, N1-2, M0). Proc Am Soc Clin Oncol 2005;23:11s. Abstract 530.
24. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-62.
25. Thurlimann BJ, Keshaviah A, Mouridsen H et al. BIG 1-98: randomized, double-blind phase III study to evaluate letrozole vs tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Proc Am Soc Clin Oncol 2005;23:6s. Abstract 511.
26. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-1802.
27. Coombes RC, Hall E, Snowdon CF et al. The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen - updated survival analysis. Breast Cancer Res Treat 2004;88(suppl 1):S7.
28. McCloskey E, Eastell R, Lakner G et al. Initial results from the LEAP study: the first direct comparison of safety parameters between aromatase inhibitors in healthy postmenopausal women. Breast Cancer Res Treat 2005;94(suppl 1):s101. Abstract 2052.